Marcel H A Muskiet,Beatrice Bottini,Sander Kooijman et al.
Marcel H A Muskiet et al.
Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial [0.03%]
马扎图肽治疗肥胖或超重成人疗效和安全性的美国多中心2期随机双盲安慰剂对照临床试验
Stanley H Hsia,Harold E Bays,Liana K Billings et al.
Stanley H Hsia et al.
Background: Therapies targeting GLP-1 or glucose-dependent insulinotropic polypeptide (GIP) receptors have provided efficacious weight reduction in adults with obesity. Mazdutide, a glucagon and GLP-1 receptor dual agonis...
Roman Vangoitsenhoven,Bart Van der Schueren,Chantal Mathieu et al.
Roman Vangoitsenhoven et al.
Safety and tolerability of orforglipron in Japanese people with type 2 diabetes [0.03%]
奥forglipron治疗2型糖尿病的日本患者的耐受性和安全性
Michael A Nauck,Michael Horowitz
Michael A Nauck
Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial [0.03%]
日本2型糖尿病患者的口服orforglipron长期安全性的ACHIENVE-J研究：一项多中心、随机、开放标签、平行对照的三期临床试验
Daisuke Yabe,Toshihiko Shiraiwa,Hiroyuki Ugai et al.
Daisuke Yabe et al.
Background: Orforglipron, an oral GLP-1 receptor agonist, requires further evaluation in east Asian populations with type 2 diabetes, given this group's distinct pathophysiological characteristics. This study aimed to ass...
Talha Burki
Talha Burki
Do weight loss and weight cycling present a clinically meaningful risk in older patients? [0.03%]
老年人减重及体重波动的临床意义风险有多大？
Henning T Langer,Ursula Müller-Werdan,Stefan D Anker et al.
Henning T Langer et al.
Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial [0.03%]
一项在中国超重或肥胖成人中评估司美格鲁肽一周一次2.4毫克疗效和安全性的III期随机、双盲、安慰剂对照、多中心试验（STEP 12）
Lixin Guo,Xiaolei Bao,Kuo-Chin Huang et al.
Lixin Guo et al.
Background: Semaglutide 2·4 mg is a GLP-1 receptor agonist that reduces bodyweight, and provides other cardiometabolic benefits, among people with a BMI at least 30 kg/m2 or at least 27 kg/m2 and with weight-related como...
Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis [0.03%]
利拉鲁肽对SELECT、FLOW和SOUL试验中肾脏结果的影响：一项既定的汇总分析
Johannes F E Mann,Sunil V Badve,Florian M M Baeres et al.
Johannes F E Mann et al.
Background: The GLP-1 receptor agonist semaglutide reduces clinically important kidney outcomes in people with type 2 diabetes and chronic kidney disease (CKD). We aimed to assess the pooled effects of semaglutide on kidn...